Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Graft-versus-host Disease (GvHD)
100%
Randomized Phase II Trial
100%
Phase II Trial
100%
Pomalidomide
100%
Overall Response Rate
57%
Sclerotic
42%
Adverse Events
28%
High Dose
28%
National Institutes of Health
28%
Effective Therapy
28%
Safe Therapy
28%
Skin Manifestations
28%
Confidence Interval
14%
Regulatory T Cells
14%
Moderate to Severe
14%
Antifibrotic
14%
Corticosteroids
14%
Interleukin-2
14%
Safety Efficacy
14%
Disease Response
14%
Partial Response
14%
Systemic Therapy
14%
Starting Dose
14%
Fascia
14%
Response Criteria
14%
Line of Therapy
14%
Body Surface Area
14%
Difficult-to-treat
14%
Lymphopenia
14%
Therapeutic Challenges
14%
Intention-to-treat Analysis
14%
Phase II Clinical Trial
14%
Recommended Dose
14%
Bacterial Pneumonia
14%
Subsequent Line
14%
Steroid-refractory
14%
Corticosteroid-refractory
14%
Medicine and Dentistry
Chronic Graft Versus Host Disease
100%
Pomalidomide
100%
Adverse Event
28%
Drug Megadose
28%
Low Drug Dose
28%
Skin Manifestation
28%
Infection
14%
Clinical Trial
14%
Intention-to-Treat Analysis
14%
Systemic Therapy
14%
Interleukin 2
14%
Fascia
14%
Lymphocytopenia
14%
Drug Dose Reduction
14%
Regulatory T Cell
14%
Body Surface
14%
Bacterial Pneumonia
14%
Recommended Drug Dose
14%
Immunology and Microbiology
Chronic Graft Versus Host Disease
100%
Pomalidomide
100%
Low Drug Dose
28%
Drug Megadose
28%
Regulatory T Cell
14%
Interleukin 2
14%
Lymphocytopenia
14%
Body Surface
14%
Surface Area
14%
Drug Dose Reduction
14%
Fascia
14%
Recommended Drug Dose
14%
Infection
14%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Graft Versus Host Disease
100%
Pomalidomide
100%
Adverse Event
28%
Skin Manifestation
28%
Infection
14%
Clinical Trial
14%
Interleukin 2
14%
Bacterial Pneumonia
14%
Lymphocytopenia
14%